Citation Impact
Citing Papers
Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
2012 Standout
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
2016 Standout
Oncogenic activation of the Notch1 gene by deletion of its promoter in Ikaros-deficient T-ALL
2010 StandoutNobel
Endemic Burkitt lymphoma: a 28-day treatment schedule with cyclophosphamide and intrathecal methotrexate
2009
Statistical analysis of relation between plasma methotrexate concentration and toxicity in high‐dose methotrexate therapy of childhood nonHodgkin lymphoma
2014
Childhood and adolescent cancer survival in the US by race and ethnicity for the diagnostic period 1975‐1999
2008
Acute lymphoblastic leukaemia
2008
Integrins in cancer: biological implications and therapeutic opportunities
2009 Standout
TRAIL and Other TRAIL Receptor Agonists as Novel Cancer Therapeutics
2009
Current management and challenges of malignant disease in the CNS in paediatric leukaemia
2008
Childhood acute lymphoblastic leukaemia – current status and future perspectives
2001
Combined systemic and intraventricular chemotherapy in primary CNS lymphoma: a pilot study
2001
Survivors of childhood and adolescent cancer: life-long risks and responsibilities
2013 Standout
From Krebs to clinic: glutamine metabolism to cancer therapy
2016 Standout
Targeting apoptosis in cancer therapy
2020 Standout
Treatment of Acute Lymphoblastic Leukemia
2006
Crizotinib (PF-2341066) induces apoptosis due to downregulation of pSTAT3 and BCL-2 family proteins in NPM-ALK+ anaplastic large cell lymphoma
2014
Recurrent loss of heterozygosity in 1p36 associated with TNFRSF14 mutations in IRF4 translocation negative pediatric follicular lymphomas
2013
Targeted therapy for Hodgkin lymphoma and systemic anaplastic large cell lymphoma: focus on brentuximab vedotin
2013
Strategies and challenges for the next generation of antibody–drug conjugates
2017 Standout
Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents
2006
Primary brain tumours in adults
2012 Standout
The anti-angiogenic basis of metronomic chemotherapy
2004 Standout
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
2014 Standout
Lessons from the past: Opportunities to improve childhood cancer survivor care through outcomes investigations of historical therapeutic approaches for pediatric hematological malignancies
2011
Apo2L/TRAIL and the Death Receptor 5 Agonist Antibody AMG 655 Cooperate to Promote Receptor Clustering and Antitumor Activity
2014
Childhood acute lymphoblastic leukemia
2002
Developmental Pharmacology — Drug Disposition, Action, and Therapy in Infants and Children
2003 Standout
Incidence of tumor lysis syndrome in children with advanced stage Burkitt's lymphoma/leukemia before and after introduction of prophylactic use of urate oxidase
2003
Childhood and adolescent cancer statistics, 2014
2014 Standout
The Tumor Lysis Syndrome
2011 Standout
Glucarpidase (Carboxypeptidase G2) Intervention in Adult and Elderly Cancer Patients with Renal Dysfunction and Delayed Methotrexate Elimination After High-Dose Methotrexate Therapy
2007
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
2009 Standout
Allogeneic hematopoietic stem cell transplantation in children and adolescents with recurrent and refractory Hodgkin lymphoma: an analysis of the European Group for Blood and Marrow Transplantation
2009
Guidelines for the Management of Pediatric and Adult Tumor Lysis Syndrome: An Evidence-Based Review
2008 Standout
Phase I Trial and Pharmacokinetic Study of Lexatumumab in Pediatric Patients With Solid Tumors
2012
Cancer treatment and survivorship statistics, 2016
2016 Standout
Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma
2004
Enhancement of antitumor properties of TRAIL by targeted delivery to the tumor neovasculature
2008
Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital
2004
Cancer treatment and survivorship statistics, 2014
2014 Standout
Preventing and Managing Toxicities of High-Dose Methotrexate
2016 Standout
Works of Georg Mann being referenced
Precursor B-cell lymphoblastic lymphoma in childhood and adolescence: Clinical features, treatment, and results in trials NHL-BFM 86 and 90
2000
Expression of tumour necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptors and sensitivity to TRAIL-induced apoptosis in primary B-cell acute lymphoblastic leukaemia cells
2000
The impact of age and gender on biology, clinical features and treatment outcome of non‐Hodgkin lymphoma in childhood and adolescence
2005
Feasibility and Toxicity of Intrathecal Liposomal Cytarabine in 5 Children and Young Adults With Refractory Neoplastic Meningitis
2007
Impact of the Methotrexate Administration Dose on the Need for Intrathecal Treatment in Children and Adolescents With Anaplastic Large-Cell Lymphoma: Results of a Randomized Trial of the EICNHL Group
2009
Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: A report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90.
1999
Diagnostic Cerebrospinal Fluid Examination in Children With Acute Lymphoblastic Leukemia: Significance of Low Leukocyte Counts With Blasts or Traumatic Lumbar Puncture
2003
Salvage Therapy of Progressive and Recurrent Hodgkin’s Disease: Results From a Multicenter Study of the Pediatric DAL/GPOH-HD Study Group
2005
Impact of Cranial Radiotherapy on Central Nervous System Prophylaxis in Children and Adolescents With Central Nervous System–Negative Stage III or IV Lymphoblastic Lymphoma
2006
Relapsed or Refractory Anaplastic Large-Cell Lymphoma in Children and Adolescents After Berlin-Frankfurt-Muenster (BFM)–Type First-Line Therapy: A BFM-Group Study
2011